TAM
ANIK icon

Tocqueville Asset Management’s Anika Therapeutics ANIK Stock Holding History

Tocqueville Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,121
Closed -$98K – 884
2014
Q2 		$98K Buy
2,121
+241
+13% +$10.7K ﹤0.01% 1155
2014
Q1 		$77K Buy
+1,880
New +$69.9K ﹤0.01% 976

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Tocqueville Asset Management's ANIK Position: Q3 2014 in Review

Tocqueville Asset Management sold out of Anika Therapeutics (ANIK) in Q3 2014, closing a stake of 2,121 shares — an estimated $98K sold.

Tocqueville Asset Management first reported a position in ANIK in Q1 2014 and held it in 2 quarters. The position peaked at $98K in Q2 2014. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

  • Tocqueville Asset Management reported no remaining Anika Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Tocqueville Asset Management sold 2,121 Anika Therapeutics shares in Q3 2014, an estimated $98K.
  • Tocqueville Asset Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 2 quarters.
  • Tocqueville Asset Management's Anika Therapeutics position peaked at $98K in Q2 2014.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on Tocqueville Asset Management's 13F filing for Q3 2014, filed 30 Oct 2014.